【目的】评估辛麻颗粒 （由细辛、射干、五味子、蜜麻黄、陈皮、制半夏等组成） 联合穴位贴敷在痰瘀阻肺型慢性咳嗽治疗中的效果。 【方法】采用回顾性研究方法，选取2022年4月至2023年4月在广东省第二中医院呼吸科门诊就诊的72例痰瘀阻肺型慢性咳嗽患者，依据治疗方法的不同将其分为观察组和对照组，每组各36例。对照组给予复方甲氧那明胶囊治疗，观察组在对照组的基础上给予辛麻颗粒联合穴位贴敷治疗，疗程为1周。观察2组患者治疗前后肺功能指标第1秒用力呼气量 （FEV1 ） 、中医证候积分、生活质量莱彻斯特咳嗽问卷 （LCQ） 评分的变化情况，并评估2组患者的临床疗效和不良反应发生情况。 【结果】（1） 临床疗效方面，治疗1周后，观察组的临床控制率和总有效率分别为44.44% （16/36） 、97.22%（35/36） ，对照组分别为16.67% （6/36） 、94.44% （34/36） ；2组患者的总有效率比较 （χ2检验） ，差异无统计学意义 （P＞0.05） ，但观察组的临床控制率 （χ2检验） 和总体疗效 （秩和检验） 均明显优于对照组 （P＜0.05） 。 （2） 肺功能方面，治疗后，2组患者的肺功能指标FEV1均较治疗前升高 （P＜0.05） ，且观察组对肺功能指标FEV1的升高作用有优于对照组趋势，但差异无统计学意义（P＞0.05） 。 （3） 生活质量方面，治疗后，2组患者的LCQ评分均较治疗前升高 （P＜0.05） ，且观察组对LCQ评分的升高作用明显优于对照组 （P＜0.05） 。 （4） 中医证候积分方面，治疗后，2组患者的中医证候积分均较治疗前明显降低 （P＜0.05） ，且观察组对中医证候积分的降低作用明显优于对照组 （P＜0.05） 。 （5） 不良反应方面，观察组和对照组的不良反应发生率均较低，均为5.56% （2/36） ，组间比较，差异无统计学意义 （P＞0.05） 。 【结论】辛麻颗粒联合穴位贴敷治疗痰瘀阻肺型慢性咳嗽，能有效提升临床疗效，显著改善患者的生活质量，且具有较高的安全性。

Objective To evaluate the efficacy of Xinma Granules （mainly composed of Asari Radix et Rhizoma，Belamcandae Rhizomas，Schisandrae Chinensis Fructus，honey-prepared Ephedrae Herba，Citri Reticulatae Pericarpium and Pinelliae Rhizoma Praeparatum） combined with acupoint application in the treatment of chronic cough with phlegm and stasis obstructing the lung type. Methods A retrospective study was conducted in 72 outpatients from the Department of Respiratory Medicine，Guangdong Second Traditional Chinese Medicine Hospital from April 2022 to April 2023，which suffered from chronic cough of phlegm and stasis obstructing the lung type. The patients were divided into the observation group and the control group according to the treatment method， with 36 patients in each group. The control group was treated with Compound Methoxyphenamine Capsules，and the observation group was treated with Xinma Granules combined with acupoint application on the basis of treatment for the control group. The treatment course for the two groups covered one week. Before and after the treatment，the changes of pulmonary function indicators of forced expiratory volume in one second （FEV1），traditional Chinese medicine （TCM） syndrome scores，and Leicester Cough Questionnaire （LCQ） scores for the quality of life in the two groups were observed. After treatment， the clinical efficacy and adverse reaction occurrence in the two groups of patients were evaluated. Results （1） After one week of treatment，the disease control rate and total effective rate in the observation group were 44.44% （16/36） and 97.22% （35/36） ，and those in the control group were 16.67% （6/36） and 94.44% （34/36） ，respectively；the intergroup comparison showed that the difference of the total effective rate （by chi-square test） in the two groups was not statistically significant （P＞0.05），but the disease control rate （by chi-square test） and the total efficacy （by rank sum test） of the observation group were significantly superior to those of the control group （P＜0.05） . （2） After treatment，the lung function indicators of FEV1 in the two groups were higher when compared with those before treatment （P＜0.05） ，and the increase of FEV1 in the observation group tended to be superior to that in the control group，without statistically significant difference （P＞0.05） . （3） After treatment，the LCQ scores for the quality of life in the two groups were increased compared with those before treatment P 0.05 and the increase of LCQ score in theobservation group was significantly superior to that in the control group （P＜0.05） . （4） After treatment，the TCM syndrome scores in the two groups were significantly lower when compared with those before treatment （P＜0.05） ，and the decrease of LCQ score in the observation group was significantly superior to that in the control group （P＜0.05） . （5） The incidence of adverse reactions in the observation group and the control group was all 5.56% （2/36） ，and the intergroup comparison showed that the difference was not statistically significant （P＞0.05） . Conclusion Xinma Granules combined with acupoint application is effective and safe in the treatment of chronic cough with phlegm and stasis obstructing the lung type by enhancing the clinical efficacy and significantly improving the quality of life of patients.

R256.11

广东省中医药局科研项目 （编号：20211028）